Time to be listed for Biogen’s spin-off Bioverativ

Biogen announced that NASDAQ authorities have given the green light to the quotation of its spin-off Bioverativ. Bioverativ, founded last December 20th, operates in the treatment areas of hemophilia and other rare blood disorders. The company is currently marketing two products: Eloctate, an antihemophilic factor, and Alprolix, a coagulation factor treating hemophilia A and B. The company’s pipeline boasts two leading products—BIVV 001 and BIVV 002. (Source Biogen)